Sensor-Controlled Scalp Cooling to Prevent Chemotherapy-Induced Alopecia in Female Cancer Patients

Fehr, Mathias K.; Welter, JoEllen; Sell, Wieland; Jung, Roman; Felberbaum, R.

doi:10.3747/co.23.3200

Cited by 17 publications

(18 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to protect the hair follicles from the peak toxicity of the chemotherapy agent, the post‐cooling time ranged from 30 to 150 min depending on the specific chemotherapy regimen (Nangia et al, 2017): it was 120 min for EC, 90 min for TC and 60 min for weekly paclitaxel (Fehr et al, 2016).…”

Section: Methodsmentioning

confidence: 99%

“…The DigniCap System has been demonstrated effective in about 50%–60% of EBC patients receiving adjuvant chemotherapy with anthracycline and taxane (Fehr, Welter, Sell, Jung, & Felberbaum, 2016; Rugo et al, 2017; Vasconcelos, Wiesske, & Schoenegg, 2018): its efficacy mainly depends on type of chemotherapeutic agent, dose and number of cycles administered (Chan et al, 2018; Friedrichs & Carstensen, 2014; Schaffrin‐Nabe, Schmitz, Josten‐Nabe, Von Hehn, & Voigtmann, 2015). The DigniCap is generally well tolerated with reportedly limited side effects (e.g.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of the DigniCap System in preventing chemotherapy‐induced alopecia in breast cancer patients is not related to patient characteristics or side effects of the device

Pedersini

Fornaro

Mauro

et al. 2020

Int J of Nursing Practice

View full text Add to dashboard Cite

Background The DigniCap System is an effective scalp cooling device for the prevention of chemotherapy‐induced alopecia in early breast cancer patients. Aim This prospective study was designed to confirm the efficacy and tolerability of the device, to explore potential factors associated with its efficacy and to collect data on patient perceptions and satisfaction. Methods Between January 2016 and June 2018, 163 early breast cancer patients eligible for adjuvant chemotherapy were enrolled. Hair loss was assessed using the Dean scale, where a score of 0–2 (hair loss ≤50%) was defined as successful. Results Hair preservation was successful in 57% of patients in the overall series. The proportion was even higher (81%) in the patient subgroup treated with a paclitaxel and trastuzumab regimen. Side effects (feeling cold, headache, head heaviness, scalp and cervical pain) were mild to moderate and did not correlate with the rate of hair loss. Lifestyle, anthropometric factors and hair characteristics failed to be associated with device efficacy. Conclusions The DigniCap System was well tolerated and found to be effective in preventing alopecia in early breast cancer patients. Our study failed to identify factors other than type of chemotherapy regimen associated with hair preservation.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Efficacy of the DigniCap System in preventing chemotherapy‐induced alopecia in breast cancer patients is not related to patient characteristics or side effects of the device

Pedersini

Fornaro

Mauro

et al. 2020

Int J of Nursing Practice

View full text Add to dashboard Cite

show abstract

“…Consider scalp cooling to reduce incidence of alopecia for patients receiving chemotherapy with high rates of alopecia. 170…”

Section: Management After Primary Surgerymentioning

confidence: 99%

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Armstrong

Alvarez

Bakkum-Gamez³

et al. 2021

Journal of the National Comprehensive Cancer Network

439

356

View full text Add to dashboard Cite

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and is the country’s fifth most common cause of cancer mortality in women. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. These NCCN Guidelines discuss cancers originating in the ovary, fallopian tube, or peritoneum, as these are all managed in a similar manner. Most of the recommendations are based on data from patients with the most common subtypes─high-grade serous and grade 2/3 endometrioid. The NCCN Guidelines also include recommendations specifically for patients with less common ovarian cancers, which in the guidelines include the following: carcinosarcoma, clear cell carcinoma, mucinous carcinoma, low-grade serous, grade 1 endometrioid, borderline epithelial, malignant sex cord-stromal, and malignant germ cell tumors. This manuscript focuses on certain aspects of primary treatment, including primary surgery, adjuvant therapy, and maintenance therapy options (including PARP inhibitors) after completion of first-line chemotherapy.

show abstract

“…Discussion of the risk and prevalence of pCIA following taxane treatment should form part of the informed consent process. Although results of scalp cooling are inconsistent, studies confirm that it reduces the risk of chemotherapy-associated alopecia in a proportion of patients and it should be routinely offered, if available, to enable a reduction in the risk of ongoing psychological morbidity associated with pCIA (Betticher et al, 2013;Cigler et al, 2015;Fehr et al, 2016;Hurk et al, 2010Hurk et al, , 2012Komen et al, 2016;Mols et al, 2009;Rice et al, 2018).…”

Section: Discussionmentioning

confidence: 99%

Permanent hair loss associated with taxane chemotherapy use in breast cancer: A retrospective survey at two tertiary UK cancer centres

et al. 2020

View full text Add to dashboard Cite

Purpose: Taxane chemotherapy is commonly used in the management of breast cancer. Hair loss (alopecia) is an expected side effect which may have a significant effect on quality of life. Alopecia is normally temporary but permanent chemotherapy-induced alopecia (pCIA) is increasingly recognised especially following docetaxel chemotherapy. However, the prevalence following docetaxel is not well understood and there is no published literature for paclitaxel chemotherapy. The aim of this study is to investigate the prevalence and patterns of pCIA resulting from both docetaxel and paclitaxel chemotherapy at two tertiary UK cancer centres. Methods: In collaboration between Clatterbridge Cancer Centre and The Christie NHS Foundation Trusts, a retrospective survey was conducted for breast cancer patients who had received taxane chemotherapy in the neoadjuvant and adjuvant settings. Patients who had concluded chemotherapy at least a year previously were contacted by post and invited to participate by completing a questionnaire and returning it to their treatment centre. Data collected included the incidence and pattern of pCIA using the Savin pictorial hair loss scale, and the methods used by patients to manage it. Fisher's exact test was used to compare pCIA between the docetaxel and paclitaxel cohorts.Results: 383 patients responded to the survey (a 63.3% overall response rate). These comprised 245 patients receiving docetaxel and 138 patients treated with paclitaxel.pCIA was reported by 23.3% of patients receiving docetaxel and 10.1% paclitaxel (p < 0.01). Overall 16.7% of patients in both groups reported the ongoing use of products or appliances such as wigs to camouflage their pCIA. In the docetaxel group, pCIA appeared to be more frequent in post-menopausal women than peri-or premenopausal women (37.8%, 12.3% and 19.6% respectively [Chi-square test p < 0.01]).Also in the docetaxel group, there appeared to be a trend for more severe scalp alopecia when the patient also received an aromatase inhibitor (AI) or tamoxifen and this difference was most marked in those who had received both an AI and tamoxifen as components of their treatment regime (p = 0.04). The use of scalp cooling was How to cite this article: Chan J, Adderley H, Alameddine M, et al. Permanent hair loss associated with taxane chemotherapy use in breast cancer: A retrospective survey at two tertiary UK cancer centres. Eur J Cancer Care.

show abstract

Sensor-Controlled Scalp Cooling to Prevent Chemotherapy-Induced Alopecia in Female Cancer Patients

Abstract: Background Scalp cooling has been used since the 1970s to prevent chemotherapy-induced alopecia, one of the

Cited by 17 publications

References 23 publications

Efficacy of the DigniCap System in preventing chemotherapy‐induced alopecia in breast cancer patients is not related to patient characteristics or side effects of the device

Efficacy of the DigniCap System in preventing chemotherapy‐induced alopecia in breast cancer patients is not related to patient characteristics or side effects of the device

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Permanent hair loss associated with taxane chemotherapy use in breast cancer: A retrospective survey at two tertiary UK cancer centres

Contact Info

Product

Resources

About